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Trends in HPV Vaccine Initiation and Completion
among Girls in Texas: Behavioral Risk Factor
Surveillance System Data, 2008–2010
Tatjana Gazibara, MD, PhD*†; Haomiao Jia, PhD‡; Erica I. Lubetkin, MD, MPH*
Objective: The objective of this study was to evaluate the trend of HPV vaccine
initiation and completion among girls in Texas from 2008 to 2010.
Methods: Data were obtained from the Behavioral Risk Factors Surveillance
System (BRFSS) over 3 years (2008–2010). The information regarding HPV vaccination
was gathered from the parents of 9- to 17-year-old daughters (choosing only 1 per
household) in randomly selected households in the sample area.
Results: The highest prevalence of vaccine initiation and completion were detected
in 2010 (20.9% and 9.7%, respectively). Over the study period, HPV vaccine initiation
statistically significantly increased (2008, 14.9%; 2009, 20.7%; 2010, 24.3%; p =
0.002), corresponding to an annual increase in coverage of 33.5% (odds ratio [OR] =
1.33; 95% confidence interval [CI]: 1.11–1.60). Similarly, HPV vaccination completion
increased (2008, 6.3%; 2009, 9.6%; 2010, 11.6%; p = 0.021), corresponding to an
annual increase in coverage of 37.1% (OR = 1.37; 95% CI: 1.05–1.79). Increasing trends
in HPV vaccination initiation and completion were observed in mothers, white, nonHispanic parents, parents who had attended some college or were college graduates,
parents who were married/partnered, and parents who lived in urban areas.
Conclusion: Although HPV vaccination coverage in Texas is lower than
recommended, there have been increases in the trends of vaccine initiation and
completion. The campaigns promoting HPV vaccination should target specific
population groups in which HPV immunization rates did not increase over time.
[P R Health Sci J 2017;36:152-158]
Key words: HPV vaccination, Trend, Girls, Texas

I

n 2007 the Advisory Committee on Immunization
Practices (ACIP) recommended routinely administering a
quadrivalent HPV vaccine to females aged 9 to 26 years, with
females aged 11 to 12 comprising the target (with associated age
range) for the vaccination (1, 2). In the United States (US), the
cost of HPV vaccination is covered by health insurance as well
as the federal Vaccines for Children program (3). Additionally,
numerous states have introduced legislation to require the
HPV vaccine, fund the vaccine, or educate the public about
the vaccine (4).
Previous analyses of the data from the Behavioral Risk Factor
Surveillance System (BRFSS) highlighted variations in the
coverage of the HPV vaccine in girls aged 14 to 17 across 6 states
(5). Pruitt et al.’s study indicated that the lowest rate (20.6%)
of HPV vaccination (≥1 vaccine injection) was reported in
Texas, while the highest (50.4%) was observed in New York
(5). Despite an attempt to make HPV vaccination mandatory
in Texas in 2007 (6), the rate of vaccine coverage remained
the lowest of the states surveyed in the following year (5).
Furthermore, cancer registry data suggested that most counties
in Texas had low compliance of cervical cancer screening
among adult women, while the incidence and mortality of that

152

particular cancer in the state remained high (7). Thus, low
vaccine coverage in this population could lead to the persistence
of cancer burden associated with HPV infection in the following
decades (8).
Although a recent rise in the rate of HPV vaccination has been
observed at the national level, the coverage in Texas remains one
of the lowest in the country (9). Given that HPV is the most
common sexually transmitted disease (10) and is the principal
risk factor for the development of cervical cancer later in life
(11), there is an increasing concern that full HPV vaccination
coverage of girls aged 13 to 15 will not reach the US Department
of Health and Human Services Healthy People 2020 goal of
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80% by 2020 (12). Furthermore, the President’s Cancer Panel
(12) considers the increasing of HPV vaccination rates to be a
national priority: Current disparities in vaccination uptake could
(probably will) later lead to like disparities in cervical cancer
incidence. For this reason, in order to increase HPV vaccination
uptake, the panel has suggested, then, that reducing the number
of missed opportunities for recommending or administering
(or both) the vaccine to eligible adolescents would result in
increasing the uptake of the vaccination, as would maximizing
the acceptance of the vaccine by parents and caregivers and
overall access to it (12).
Because of the continuously low proportion of females who
are being immunized against the HPV infection in Texas, it is
necessary to identify whether there is a change in the trajectory
of HPV vaccine coverage; particular attention must be paid to
the disparities experienced by certain population subgroups
The aim of the BRFSS survey was to evaluate the trends of HPV
vaccine initiation and completion among adolescent females in
Texas from 2008 to 2010 and to describe potential disparities
in HPV vaccination among girls in the population of that state.

Materials and Methods
Behavioral risk factor surveillance system
The Centers for Disease Control and Prevention’s BRFSS is a
state-based telephone interview survey conducted each year to
monitor the health-related behaviors, chronic health conditions,
and use of preventive services of US citizens aged 18 and above
(13). State-level sampling and weighting was used to obtain a
representative sample (in each state) of the general population
living in households with land telephones. Post-stratification,
the method of choice for weighting data in the BRFSS,
consisted of simultaneously adjusting for age, race/ethnicity,
sex, geographic region, and other characteristics to those
proportions identified in the US Census (14). As of 2006, a more
sophisticated weighting method was used; it included iterative
proportional fitting, which allowed researchers to adjust for
each variable individually in a series of data processing–intensive
iterations. Finally, the weights were adjusted until the sample
weights were deemed representative of the population (14).
The BRFSS survey consists of core modules, optional modules,
and state-added questions. The child HPV-vaccination module
is optional and is not used assessed in all states. Furthermore,
this module was not used in BRFSS surveys after 2010.
Data collection
Data on child HPV vaccination were available for 3
consecutive years (2008, 2009, 2010). Because of changes in
the data collection (the inclusion of households with cellular
telephones, only), including analyses that cross over from 2010
to 2011 is not recommended as such analyses have the potential
to influence the validity of survey results (14). The dataset for
our survey included residents of Texas, exclusively. The choice to
include only the members of that population in our sample was
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made based on the availability of said residents as well as their
having already been surveyed using the “child HPV vaccination”
optional module for several consecutive years. The information
regarding HPV vaccination was gathered from the parents of
randomly selected children, aged 9 to 17 years. The analyses
included girls, only, because data regarding boys were collected
only for 2010. The HPV vaccination status was evaluated by
asking “Has this child ever had an HPV vaccination?” followed
by “How many HPV shots did she receive?” Parents who
responded affirmatively to the former question were considered
to have initiated the HPV vaccination. Other variables in the
analysis were race/ethnicity (non-Hispanic white, non-Hispanic
black, Hispanic, and other), level of education (high school or
less/some college or more), income of parents (<$50,000 vs. ≥
$50,000 annual income), and the geographic area in which the
household was located (urban, suburban, rural). Information
regarding whether the responding parent had undergone a
routine check-up in the year prior to the survey (yes, no) was
also taken into consideration.
The Institutional Review Board (IRB) of the City College
of New York considered the ethical aspects of this research
and determined that this analysis did not qualify as “human
subject research” as defined by federal regulations (45 CFR
46.102(d) (f)). Therefore, no further IRB review or approval
was required.
Statistical analysis
Summary statistics describing the study sample included
proportions. Vaccination coverage according to selected
categories was presented as percentages, with corresponding
95% confidence intervals (CI). All estimates were adjusted for
unequal probability sampling weight and post-stratification.
When calculating 95% CIs and p-values, we adjusted for the
multistage sampling design of the BRFSS survey. Linear trend
was analyzed for HPV vaccine initiation (first dose) and for HPV
vaccination completion (all 3 doses received). In the equation
estimating linear trend, the dependent variables were HPV
coverage rates for each of the 3 years, according to parental sociodemographic characteristics, while the independent variable was
time (2008–2010). Odds ratios (OR) and corresponding 95%
CIs were calculated to assess the increase in trend per year. A
probability level of p less than 0.05 was considered statistically
significant. The statistical analysis was performed using the SAS
software package, version 9.3.

Results
For the period of 2008 to 2010, there were a total of 3,085
parents whose children were eligible for HPV vaccination. The
socio-demographic characteristics of these parents are shown in
Table 1. Most respondents were non-Hispanic whites (48.3%),
had attended some college or were college graduates (59.1%),
were married (70.8%) and had 1 child in their household
(42.2%), had a household income of $50,000 or more (51.7%),
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Table 1. Socio-demographic characteristics of parents of children eligible to be
vaccinated for HPV who participated in the 2008–2010 BRFSS survey in Texas

household (p = 0.021; 48% increase/year), parents
who lived in urban areas (p = 0.018; 33% increase/
year), and parents who had had a routine check-up in
Year
the year prior to the survey (p<0.001; 80% increase/
Variable
2008
2009
2010
Overall
year) (Table 3). We observed this trend in families
n (%)
n (%)
n (%)
with annual incomes of both less than $50,000 and
$50,000 and higher (Table 3). By 2010, the highest
Totals
791 (100.0) 833 (100.0) 1461 (100.0) 3085 (100.0)
Sex
initiation rate was 37%, and most subgroups had
Female
555 (70.1)
531 (63.7)
973 (66.6)
2059 (66.7)
initiation rates ranging from 20% to 28%.
Male
236 (29.9)
302 (36.3)
488 (33.4)
1026 (33.3)
Similar to what we noted regarding vaccine
Race/Ethnicity
initiation, we observed an overall increase in
Non-Hispanic white
418 (52.8)
439 (52.7)
632 (43.3)
1489 (48.3)
Non-Hispanic black
64 (8.1)
70 (8.4)
99 (6.8)
233 (7.5)
the tendency to complete the process of HPV
Hispanic
280 (35.4)
284 (34.1)
680 (46.5)
1244 (40.3)
vaccination (2008, 6.3%; 2009, 9.6%; 2010, 11.6%; p
Other
29 (3.7)
40 (4.8)
50 (3.4)
119 (3.9)
= 0.021) (Table 3). The estimated annual increase in
Education
coverage of all 3 doses of HPV vaccine (vaccination
High school or less
313 (39.6)
302 (36.2)
648 (44.3)
1263 (40.9)
Some college or more 478 (60.4)
531 (63.8)
813 (55.7)
1822 (59.1)
completion) was 37.1% (OR = 1.37; 95% CI:
Marital status
1.05–1.79). A statistically significant increase in the
Married/partnered
546 (69.0)
596 (71.6)
1041 (71.2)
2183 (70.8)
trend of HPV completion was registered in mothers
Divorced
144 (18.2)
132 (15.8)
236 (16.2)
512 (16.6)
Other
101 (12.8)
105 (12.6)
184 (12.6)
390 (12.6)
(p = 0.008; 39% increase/year), white, non-Hispanic
Number of children
parents (p = 0.001; 71% increase/year), parents who
in household
had attended some college or were college graduates
1
363 (45.9)
345 (41.4)
594 (40.7)
1302 (42.2)
(p = 0.009; 50% increase/year), parents who were
2
246 (31.1)
305 (36.6)
464 (31.8)
1015 (32.9)
≥3
182 (23.0)
183 (22.0)
403 (27.5)
768 (24.9)
either married/partnered or divorced (p = 0.001;
Household income
61% increase/year and p = 0.040, 50% increase/
<$50,000 (US)
410 (51.8)
385 (46.2)
801 (54.8)
1596 (51.7)
year, respectively), parents who had 1 child in their
≥$50,000 (US)
381 (48.2)
448 (53.8)
660 (45.2)
1489 (48.3)
household (p = 0.025; 50% increase/year), parents
MSA code
Urban
419 (53.0)
512 (61.5)
882 (60.4)
1813 (58.8)
who lived in urban areas (p = 0.019; 51% increase/
Suburban
246 (31.1)
232 (27.8)
351 (24.0)
829 (26.9)
year), and parents who had not reported having had
Rural
126 (15.9)
89 (10.7)
228 (15.6)
443 (14.4)
a routine check-up in the year prior to the survey (p =
Routine check-up
0.017; 64% increase/year) (Table 4). Similar to what
in past year
Yes
497 (62.8)
498 (59.8)
839 (57.4)
1834 (59.4)
was noted in vaccine initiation, the increasing trend
No
294 (37.2)
335 (40.2)
622 (42.6)
1251 (40.6)
in HPV vaccine completion was observed in families
with annual incomes of both less than $50,000 and
Legend. MSA: metropolitan statistical area
$50,000 and higher (Table 4). By 2010, the highest
completion rate was 24.0%, and most subgroups had completion
and lived in urban areas (58.8%). More than one half (59.4%)
rates that ranged from 10% to 15%.
of the parents had had a routine check-up in the year prior to
the survey.
Table 2 displays the prevalences of HPV shots according
Discussion
to parental socio-demographic characteristics. The highest
prevalence of vaccine initiation and completion were detected
Since 2010 the BRFSS survey has not included a module
in 2010. Overall, the highest vaccination coverage in all the
for collecting HPV vaccination data for children (13). For this
examined categories was noted for 1 HPV shot. On the other
reason, the trend analysis presented in this research article
hand, the lowest prevalence was observed for vaccination
provides important findings. The results of our study show
completion (all 3 HPV shots).
that HPV vaccination initiation and completion in adolescent
Over the study period, HPV initiation statistically significantly
girls in Texas increased from 2008 to 2010 in many population
increased (2008, 14.9%; 2009, 20.7%; 2010, 24.3%; p = 0.002)
subgroups. This means that in spite of this state’s having one
(Table 3), corresponding to an annual increase in coverage of
of the lowest state coverage rates (5, 9), an overall increasing
33.5% (OR = 1.33; 95% CI: 1.11–1.60). A statistically significant
(over time) tendency in responding to HPV vaccination is
increasing trend in the rates of HPV initiation was observed in
present. Similarly, in North Carolina, an upward trend was
mothers (p = 0.008; 30% increase/year), white, non-Hispanic
observed among adolescent girls for the same period (15).
parents (p<0.001; 60% increase/year), parents who had
However, compared with girls in North Carolina (15), girls
attended some college or were college graduates (p<0.001; 54%
in Texas had roughly 2 times lower rates of overall vaccine
increase/year), parents who were married/partnered (p<0.001;
initiation (40–50% in North Carolina versus 20–28% in
Texas) in 2010.
50% increase/year), parents who had 2 children in their

154

PRHSJ Vol. 36 No. 3 • September, 2017

05 15-81 (1452) Gazibara et al.indd 154

8/23/2017 9:34:17 AM

HPV Vaccination Trends in Texas

Gazibara et al

Table 2. Prevalence of HPV shots according to parental socio-demographic
Although an increase in vaccination trend was
characteristics
noted at the state level, vaccination initiation
improved to a greater degree in certain population
HPV vaccination
groups. For instance, our results show that mothers
Variable
≥ 1 shot
≥ 2 shots
All 3 shots
were more likely to report that their daughters had
% (95% CI)
% (95% CI)
% (95% CI)
initiated and completed the vaccination process.
Regarding vaccine initiation, a similar finding was
Year
2008
14.9 (11.2–18.6)
10.4 (6.9–13.9)
6.3 (3.4–9.2)
described for girls in North Carolina (15). A rising
2009
20.6 (16.3–24.9)
13.2 (8.8–17.5)
9.6 (6.7–12.5)
trend of reporting HPV initiation was observed
2010
24.3 (20.1–28.4)
15.9 (11.8–20.0)
11.6 (8.5–14.7)
among male parents, which was at the level of
Overall
20.9 (18.5–23.2)
13.7 (11.3–16.0)
9.7 (7.9–11.5)
Sex
marginal statistical significance. Women—both
Female
23.9 (21.6–26.6)
17.0 (14.4–19.5)
12.2 (9.5–14.9)
mothers and caregivers—might be more involved
Male
15.6 (11.9–19.3)
8.6 (5.6–11.5)
5.6 (3.4–7.8)
than their male counterparts in the health and in
Race/Ethnicity
the vaccination status of the children for whom
Non-Hispanic white
19.6 (16.5–22.7)
12.4 (9.8–14.9)
9.1 (6.9–11.2)
Non-Hispanic black
27.7 (17.1–38.3)
21.6 (10.6–32.6)
17.8 (7.0–28.5)
they are responsible. Several studies suggested that
Hispanic
20.5 (16.8–24.2)
13.9 (10.7–17.0)
8.9 (6.3–11.4)
both mothers and fathers may inaccurately report
Other
13.4 (3.2–23.5)
5.7 (1.9–13.3)
0.7 (0.3–1.7)
vaccination uptake (16–18). In line with this, various
Educational attainment
authors have reported somewhat conflicting findings
High school or less
20.3 (16.6–24.0)
14.0 (10.7–17.3)
9.1 (6.2–12.0)
Some college or more 20.3 (17.4–23.2)
12.9 (10.5–15.2)
9.4 (7.2–11.5)
(16–18). Stupiansky et al. documented that, even
Marital status
though recall of vaccination had high sensitivity and
Married/partnered
19.4 (16.8–21.9)
12.4 (10.2–14.5)
8.7 (6.7–10.6)
reasonable specificity, only 76% of the participating
Divorced
25.9 (19.6–32.2)
20.3 (14.4–26.2)
12.9 (8.7–17.0)
mothers/female caregivers actually knew whether
Other
21.1 (13.8–28.3)
13.3 (6.8–19.8)
10.2 (3.9–16.4)
Number of children
their daughters/wards had received the HPV vaccine
in household
(16). Adequate accuracy in the classification of the
1
20.1 (16.5–23.6)
13.9 (11.0–16.8)
9.2 (6.8–11.5)
HPV vaccination status of daughters has also been
2
22.3 (18.0–26.6)
12.8 (9.3–16.3)
9.9 (6.8–13.0)
reported by Ojha et al. (17), while a recent report
≥3
17.9 (14.3–21.4)
13.2 (9.1–17.3)
8.7 (5.0–12.4)
Household income
using a smaller sample of parents (79 in total) than
<$50,000 (US)
20.4 (16.9–23.9)
13.5 (10.6–16.4)
8.1 (5.9–10.2)
were used in the former 2 studies reported that
≥$50,000 (US)
19.9 (16.6–23.2)
12.8 (10.1–15.5)
9.8 (7.2–12.3)
40% of parents or guardians had failed to recall the
MSA code
accurate number of HPV shots that their daughters
Urban
23.7 (20.2–27.2)
15.8 (13.0–18.5)
10.7 (8.1–13.2)
Suburban
15.8 (12.19–19.5) 11.0 (7.9–14.1)
8.9 (6.0–11.8)
had received (18). Given the reports, it is reasonable
Rural
21.2 (13.7–28.6)
11.1 (6.4–15.8)
5.0 (2.4–7.5)
to presume that parents/caregivers may under-report
Routine check-up
vaccine uptake.
in past year
Yes
22.8 (19.3–26.3)
16.0 (13.4–18.5)
11.5 (9.3–13.6)
In terms of race/ethnicity, a significant increase
No
17.1 (14.0–20.2)
9.9 (7.1–12.6)
6.5 (3.9–9.0)
in HPV vaccine initiation and completion was
observed in Texas in non-Hispanic whites. By
Legend. CI: confidence interval; MSA: metropolitan statistical area
contrast, non-Hispanic blacks had the highest rates of
vaccination in 2008 and 2010, but the coverage did not improve
with a greater likelihood of vaccination in low-income Hispanic
with time. As a result, racial/ethnic disparities may appear to
communities, physician recommendation and low concern
be lessening since some population subgroups (non-Hispanic
about paying for the vaccine have been deemed as independent
blacks) will not continue to make the same gains in health
predictors of HPV vaccine uptake (22).
experienced by others (non-Hispanic whites). Our results are
A significant increase in the proportion of physicians who
also comparable to those of the US Health Information National
always recommend HPV vaccine for female patients aged 11 or
Trends Survey (19). Specifically, white women were found to
12 years was observed from 2009 to 2011 (22). However, this
be 1.86 times more willing to vaccinate their daughters (19). In
was not noticed for patients aged 13 to 17 years (22). In North
North Carolina, however, a statistically significant increasing
Carolina, for example, an increase in vaccination initiation was
trend of initiating HPV vaccination was seen in populations
observed among those who had a regular health care provider
other than non-Hispanic whites and non-Hispanic blacks (15).
(15). According to the 2009 National Immunization SurveyData from 2009 from Hispanic populations in 3 US regions,
Teen, adolescents who received a recommendation from their
including Texas, indicated moderate levels of vaccine awareness
health care providers were 4.81 times more likely to undergo
among caregivers/parents (20). Barriers to HPV immunization
HPV vaccination, regardless of race/ethnicity, compared with
in this population included concerns about negative effects
those who did not receive such a recommendation (23). Still,
on the daughter’s sexual behavior, fertility, and overall health
racial/ethnic minorities were less likely overall to receive this
(21). Although higher levels of acculturation are associated
kind of recommendation (23). Vadaparampil et al. (24) pointed
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out that in 2009, HPV vaccination rates in Florida were higher
among the patients of pediatricians who had a private practice,
practiced in a single specialty setting, and saw primarily nonHispanic white patients. To secure higher HPV vaccination
coverage, it is essential to provide counseling and vaccination
recommendations to all population groups.
Moreover, HPV immunization completion is another emerging
issue. Although we observed an overall upward trend in vaccine
completion, fewer parents reported having their daughter complete
all 3 doses of HPV as opposed to 1 or 2 doses. One of the reasons
for suboptimal coverage may be that HPV vaccination completion
takes 3 doses (25). A randomized study by Romanowski et al. (26)
observed that immune response to a 2-dose vaccine in girls aged 9
to 14 years is comparable to the response to the standard 3-dose
series in women aged 15 to 25 years up to 4 years after the first
vaccination. This means that the use of a vaccine with fewer doses
could improve HPV vaccination completion rates. Additionally,
using a 2-dose HPV vaccine would cost less. For example, the
decision regarding whether or not to undergo HPV vaccination is
profoundly influenced by an individual’s health beliefs; however,
there is a statistically significant decrease in acceptability as the
cost of the vaccine increases (27).

Although cost issues represent a likely barrier to vaccination,
we observed significant increases in the trends of both of the
income categories included in our study. This was not the case
in North Carolina, where an upward tendency of increased
HPV vaccine initiation was observed only among families
with annual incomes of $50,000 or more (15). However, as
expected, a trend toward increased rates of immunization was
documented among parents who had attended at least some
college, both in Texas and in North Carolina (15). It was noted
that in the decision-making process as to whether to vaccinate a
daughter against HPV, 40% of the mothers in Southeast Texas
made this decision independently, whereas 22% involved
husbands/partners (28). Moreover, one third of the mothers
included their daughters in decision making (28). However,
in our study, as well as in North Carolina (15), significantly
higher HPV vaccination uptake was established among those
whose parents/guardians were married/partnered, which
may be more reflective of other correlates such as higher
socioeconomic status or social support. In terms of residence,
in 2008 the highest HPV coverage was found in metropolitan
counties (29). Similarly, over the following 2 years, a significant
increase in HPV vaccination trends was observed in urban areas.
In contrast, over the same
Table 3. Trend of HPV vaccine initiation among girls aged 9–17 in Texas, 2008–2010 BRFSS
period in North Carolina,
an increasing tendency to
HPV vaccine initiation
initiate the vaccine process
Parental characteristics 2008
2009
2010
OR (95% CI)*
Wald χ2 p
was noted in rural areas
% (95% CI)
% (95% CI)
% (95% CI)
(15). This finding suggests
Sex
that promotions of HPV
Female
18.7 (14.0–23.4) 23.9 (18.4–29.4) 28.1 (23.2–33.0) 1.30 (1.07–1.58) 6.94 0.008
vaccination should include
Male
9.5 (3.2–15.7)
17.2 (10.9–23.5) 18.8 (12.1–25.5) 1.40 (0.96–2.03) 3.09 0.079
suburban and remote areas,
Race/Ethnicity
Non-Hispanic white
10.2 (6.9–13.5) 22.3 (16.8–27.8) 24.8 (18.7–30.9) 1.60 (1.27–2.00) 15.81 <0.001
equally.
Non-Hispanic black
24.3 (3.5–45.1) 20.7 (1.8–22.5) 37.2 (20.7–53.7) 1.43 (0.69–2.95) 0.95 0.330
B ec au s e t h e B R FSS
Hispanic
17.8 (11.1–24.5) 20.0 (13.4–26.9) 23.2 (17.3–29.1) 1.18 (0.89–1.57) 1.36 0.244
s
u
r vey collects selfOther
24.1 (8.8–39.4) 16.3 (5.0–37.7) 3.3 (0.4–6.2)
0.37 (0.16–0.86) 5.34 0.020
reported
data, there may
Educational attainment
High school or less
16.8 (9.7–23.8) 23.9 (17.2–30.5) 20.4 (14.7–26.1) 1.09 (0.82–1.45) 0.33 0.566
be some misclassifications
Some college or more 13.7 (9.8–17.6) 18.5 (13.2–23.8) 26.9 (21.4–32.4) 1.54 (1.23–1.93) 13.82 <0.001
of vaccination status which
Marital status
could have caused an
Married/partnered
10.7 (7.8–13.6) 21.7 (16.8–26.6) 23.8 (19.1–28.5) 1.50 (1.24–1.83) 17.20 <0.001
over-/underestimation of
Divorced
21.6 (9.8–33.4) 35.1 (23.1–47.1) 24.3 (16.5–32.1) 1.03 (0.71–1.50) 0.03 0.858
Other
29.4 (13.1–45.7) 10.5 (3.2–17.7) 28.1 (15.9–40.2) 1.05 (0.60–1.85) 0.03 0.859
the number of respondents
Number of children
w ho actual ly had had
in household
their daughters vaccinated
1
17.1 (11.4–22.8) 17.6 (11.7–23.5) 24.9 (18.4–31.4) 1.29 (0.98–1.70) 3.36 0.067
against HPV. The sample
2
14.9 (7.4–22.3) 22.2 (15.1–29.2) 28.3 (20.6–35.9) 1.48 (1.06–2.07) 5.30 0.021
≥3
10.8 (5.1–16.5) 23.2 (13.4–33.0) 18.9 (12.0–25.8) 1.25 (0.90–1.74) 1.78 0.181
size of the racial/ethnic
Household income
group classified as “Other”
<$50,000 (US)
14.2 (9.3–9.1)
21.9 (15.0–28.8) 24.3 (18.2–30.4) 1.35 (1.05–1.75) 5.42 0.020
was much smaller than
≥$50,000 (US)
12.4 (8.1–16.7) 19.5 (13.8–25.2) 25.6 (19.3–31.9) 1.53 (1.19–1.98) 10.75 0.001
the other categories and
MSA code
Urban
19.1 (13.4–24.8) 21.4 (16.1–26.7) 28.8 (22.9–34.7) 1.33 (1.05–1.69) 5.63 0.018
might have been particularly
Suburban
12.3 (5.8–18.8) 14.1 (7.6–20.6) 19.5 (13.4–25.6) 1.33 (0.92–1.91) 2.35 0.125
heterogeneous (Asians/
Rural
8.8 (3.5–14.1)
36.4 (20.1–52.7) 20.7 (8.3–33.0)
1.35 (0.86–2.11) 1.72 0.189
American Indians/Pacific
Routine check-up
in past year
Islanders). Therefore,
Yes
6.7 (3.8–9.6)
18.8 (11.7–25.8) 23.1 (17.0–29.2) 1.80 (1.36–2.39) 16.86 <0.001
t h e t re n d a n a l y s i s i n
No
20.4 (14.7–26.1) 22.2 (17.1–27.3) 25.1 (19.6–30.6) 1.15 (0.91–1.44) 1.39 0.239
this subgroup should be
Legend. CI: confidence interval; OR: odds ratio; MSA: metropolitan statistical area, *year effect, bold values are statistically significant
interpreted with caution.
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Table 4. Trend in HPV vaccine completion among girls aged 9–17 in Texas, 2008–2010 BRFSS

Resumen

HPV vaccine completion

Objetivo: El objetivo de
este estudio fue evaluar la
tendencia de la iniciación de
Sex
la vacuna contra el VPH en
Female
7.6 (4.7–10.54) 13.6 (8.9–18.3) 14.7 (10.9–18.4) 1.39 (1.09–1.77) 7.08
0.008
las niñas en Texas desde 2008
Male
4.3 (1.4–10.0) 5.3 (2.4–8.2)
7.0 (1.9–12.1)
1.29 (0.60–2.73) 0.43
0.511
a 2010. Métodos: Los datos se
Race/Ethnicity
obtuvieron del “Behavioral
Non-Hispanic white
4.1 (1.9–6.2)
9.7 (6.2–13.2) 12.6 (8.1–17.1) 1.71 (1.25–2.34) 11.22
<0.001
Non-Hispanic black
12.7 (8.7–34.3) 17.2 (5.3–39.7) 24.0 (9.3–38.7) 1.48 (0.55–3.98) 0.59
0.440
Risk Factors Surveillance
Hispanic
7.8 (3.5–12.1) 9.4 (5.3–13.5) 9.2 (4.5–13.9)
1.08 (0.72–1.61) 0.13
0.718
System” (BRFSS) durante
Other
0 (0)
0.9 (0.8–2.7)
1.1 (0.9–3.1)
2.17 (0.43–10.90) 0.88
0.348
tres años (2008-2010).
Educational attainment
La información sobre la
High school or less
7.2 (1.3–13.1) 9.6 (5.5–13.7) 10.4 (5.5–15.3) 1.20 (0.75–1.93) 0.61
0.433
Some college or more 5.7 (2.9–8.4)
9.3 (5.4–13.2) 12.4 (8.5–16.3) 1.50 (1.10–2.05) 6.74
0.009
vacunación contra el VPH
Marital status
se recopiló de los padres
Married/partnered
3.7 (2.1–5.3)
10.1 (6.6–13.6) 11.2 (7.7–14.7) 1.61 (1.23–2.10) 12.38
<0.001
de las hijas de 9 a 17 años
Divorced
5.4 (1.7–9.1)
20.8 (9.6–32.0) 15.8 (8.5–23.0) 1.50 (1.01–2.21) 4.15
0.040
(eligiendo sólo 1 por hogar)
Other
19.5 (3.2–35.8) 3.1 (0.5–5.6)
10.4 (2.0–18.8) 0.69 (0.29–1.63) 0.72
0.396
Number of children
en los hogares seleccionados
in household
al azar. La información sobre
1
5.8 (2.5–9.1)
9.3 (5.4–13.2) 12.5 (8.0–17.0) 1.50 (1.05–2.13) 5.03
0.025
la vacunación contra el VPH
2
8.8 (1.5–16.0) 8.2 (4.5–11.9) 12.6 (6.7–18.5) 1.26 (0.74–2.15) 0.71
0.398
fue recopilada de los padres
≥3
3.4 (0.5–6.3)
12.6 (4.0–21.2) 9.4 (3.3–15.5)
1.38 (0.59–2.22) 1.76
0.184
Household income
de una hija seleccionada
<$50,000 (US)
3.8 (2.0–5.6)
8.2 (4.7–11.7) 11.9 (7.0–16.8) 1.76 (1.28–2.49) 10.28
0.001
aleatoriamente de 9 a 17 años
≥$50,000 (US)
5.6 (2.5–8.7)
10.8 (6.1–15.5) 12.1 (7.4–16.8) 1.44 (1.02–2.03) 4.36
0.037
en el hogar. Resultados: La
MSA code
iniciación de vacunación más
Urban
6.2 (2.5–9.9)
10.8 (7.1–14.5) 13.9 (9.2–18.6) 1.51 (1.07–2.13) 5.52
0.019
Suburban
7.1 (1.2–13.0) 9.0 (3.3–14.7) 10.2 (5.7–14.7) 1.22 (0.75–1.97) 0.63
0.427
alta, así como la prevalencia de
Rural
4.6 (0.9–8.3)
6.2 (1.1–11.3) 4.1 (0.2–8.0)
0.92 (0.49–1.71) 0.07
0.792
la finalización de vacunación
Routine check-up
se detectó en 2010 (20.9%
in past year
y 9.7% respectivamente). Se
Yes
8.8 (7.2–10.4) 11.4 (6.7–16.1) 13.8 (9.9–17.7) 1.28 (1.92–1.79) 5.67
0.137
No
2.5 (2.0–7.0)
7.5 (3.8–11.2) 8.5 (4.0–13.0)
1.64 (1.09–2.46) 2.21
0.017
observó aumento del inicio
de vacunación (2008, 14.9%;
Legend. CI: confidence interval; OR: odds ratio; MSA: metropolitan statistical area, *year effect, bold values are statistically significant
2009, 20.7%; 2010, 24.3%; p
Additionally, pediatricians may not routinely offer the vaccine to
= 0.002) con un aumento de cobertura de 33.5% al año (odds
ratio [OR] = 1.33, intervalo de confianza 95% [IC] 1.11-1.60).
younger girls (9 and 10 years old), which age group we included
Se observó aumento de la finalización de vacunación (2008,
in the analysis. This vaccine is proven to be safe and effective
6.3%; 2009, 9.6%, 2010, 11.6%; p=0.021) con un aumento
for girls as young as 9 but should be given before sexual debut,
de cobertura de 37.1% al año (OR=1.37, 95% IC 1.05-1.79).
and some pediatricians might feel more comfortable bringing
Ambos aumentos se observaron entre madres, los padres
up the topic of vaccination to the parents of girls who are 11
blancos que no eran hispanos, los que asistieron a universidad
or 12 (or older). Therefore, it might be that the coverages of
o eran graduados universitarios, los padres que eran casados/
initiation and completion might differ according to the age of
en una relación, y vivían en zonas urbanas. Conclusión: A pesar
the child/adolescent (9- to 10-year-olds vs. 11- to 13-year-olds,
de que la cobertura de vacunación contra el VPH en Texas es
for example).
más baja de la recomendada, hay aumentos en la tendencia de
Although HPV vaccination coverage in Texas is lower
la iniciación y finalización de vacunación. La promoción de la
than is recommended, there were significant increases in
vacunación debe dirigirse a grupos específicos de población en
the tendencies to initiate and complete the process of HPV
la que la inmunización contra el VPH no aumentó con el tiempo.
vaccination. Because HPV vaccination has a profound role
in improving public health, Campaigns promoting HPV
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